Claims for Patent: 7,498,343

Summary for Patent: 7,498,343

Title:	Mycobacterial inhibitors
Abstract:	The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) ##STR00001## the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. In particular, compounds are claimed in which, independently from each other, R.sup.1 is bromo, p=1, R.sup.2 is alkyloxy, R.sup.3 is optionally substituted naphthyl or phenyl, q=1, R.sup.4 and R.sup.5 each independently are hydrogen, methyl or ethyl, R.sup.6 is hydrogen, r is equal to 0 or 1 and R.sup.7 is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
Inventor(s):	Van Gestel; Jozef Frans Elisabetha (Beerse, BE), Guillemont; Jerome Emile Georges (Val de Reuil Cedex, FR), Venet; Marc Gaston (Le Mans, FR), Poignet; Herve Jean Joseph (Issy-les-Moulineaux Cedex 9, FR), Decrane; Laurence Francoise Bernadette (Val de Reuil Cedex, FR), Vernier; Daniel F. J. (Val de Reuil Cedex, FR), Odds; Frank Christopher (Drumoak, GB)
Assignee:	Janssen Pharmaceutica N.V. (Beerse, BE)
Application Number:	11/007,026
Patent Claims:	1. A compound according to the general Formula (Ia) or the general Formula (Ib) ##STR00079## the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof, wherein: R.sup.1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is an integer equal to zero, 1, 2, 3 or 4; R.sup.2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula ##STR00080## wherein Y is CH.sub.2, O, S, NH or N-alkyl; R.sup.3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is an integer equal to zero, 1, 2, 3 or 4; R.sup.4 and R.sup.5 each independently are hydrogen, alkyl or benzyl; or R.sup.4 and R.sup.5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl; R.sup.6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R.sup.6 radicals may be taken together to form a bivalent radical of formula --CH.dbd.CH--CH.dbd.CH--; r is an integer equal to 0, 1, 2, 3, 4 or 5; and R.sup.7 is hydrogen, alkyl, Ar or Het; R.sup.8 is hydrogen or alkyl R.sup.9 is oxo; or R.sup.8 and R.sup.9 together form the radical .dbd.N--CH.dbd.CH--. alkyl is a straight or branched-saturated hydrocarbon radical having from 1 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo; Ar is a homocycle selected from the group of-phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl; Het is a monocyclic heterocycle selected from the group of N-phenoxypiperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy; halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and haloalkyl is a straight or branched saturated hydrocarbon radical having-from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are substituted with one or more halo-atoms. 2. A compound according to claim 1, characterized in that R.sup.1 is hydrogen, halo, cyano, Ar, Het, alkyl, and alkyloxy p is an integer equal to zero, 1, 2, 3 or 4; R.sup.2 is hydrogen, hydroxy, alkyloxy, alkyloxyalkyloxy, alkylthio or a radical of formula ##STR00081## wherein Y is O; R.sup.3 is alkyl, Ar, Ar-alkyl or Het; q is an integer equal to zero, 1, 2, or 3; R.sup.4 and R.sup.5 each independently are hydrogen, alkyl or benzyl; or R.sup.4 and R.sup.5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, imidazolyl, triazolyl, piperidinyl, piperazinyl, pyrazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl and pyrimidinyl; R.sup.6 is hydrogen, halo or alkyl; or two vicinal R.sup.6 radicals may be taken together to form a bivalent radical of formula --CH.dbd.CH--CH.dbd.CH--; r is an integer equal to 1; and R.sup.7 is hydrogen; R.sup.8 is hydrogen or alkyl; R.sup.9 is oxo; or R.sup.8 and R.sup.9 together form the radical .dbd.N--CH.dbd.CH--. alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally substituted with halo or hydroxy; Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, haloalkyl, cyano, alkyloxy and morpholinyl; Het is a monocyclic heterocycle selected from the group of N-phenoxypiperidinyl, furanyl, thienyl, pyridinyl, pyrimidinyl; or a bicyclic heterocycle selected from the group of benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 alkyl substituents; and halo is a substituent selected from the group of fluoro, chloro and bromo. 3. A compound according to claim 1 or 2 wherein R.sup.6 is hydrogen, halo, alkyl. 4. A compound according to any one of claims 1, characterized in that, independently from each other, R.sup.1 is hydrogen, halo, Ar, alkyl or alkyloxy, p=1, R.sup.2 is hydrogen, alkyloxy or alkylthio, R.sup.3 is naphthyl, phenyl or thienyl, each optionally substituted with 1 or 2 substituents selected from the group of halo and haloalkyl, q=0, 1, 2 or 3, R.sup.4 and R.sup.5 each independently are hydrogen or alkyl or R.sup.4 and R.sup.5 together and including the N to which they are attached form a radical selected from the group of imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl, R.sup.6 is hydrogen, alkyl or halo, r is equal to 0 or 1 and R.sup.7 is hydrogen. 5. A compound according to claim 4, characterized in that, independently from each other, R.sup.1 is bromo, R.sup.2 is alkyloxy, R.sup.3 is naphthyl or phenyl, q=1, R.sup.4 and R.sup.5 each independently are hydrogen, methyl or ethyl and R.sup.6 is hydrogen. 6. A compound according to any one of claims 1 wherein the compound is a compound of formula (Ia). 7. A compound according to claim 1, characterized in that the compound is: 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(3,5-difluoro-phenyl)4-dimethyl- amino-1-phenyl-butan-2-ol; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-p- henyl-butan-2-ol; 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(2,5-difluoro-phenyl)4-dimethylamin- o-1-phenyl-butan-2-ol; 1-(6-bromo-2-methoxy-quinolin-3-yl)-2-(2,3-difluoro-phenyl)4-dimethylamin- o-1-phenyl-butan-2-ol; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(2-fluoro-phenyl)-1- -phenyl-butan-2-ol; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-naphthalen-1-yl-1-p- -tolyl-butan-2-ol; 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-methylamino-2-naphthalen-1-yl-1-phe- nyl-butan-2-ol; and 1-(6-bromo-2-methoxy-quinolin-3-yl)-4-dimethylamino-2-(3-fluoro-phenyl)-1- -phenyl-butan-2-ol, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide forms thereof. 8. A compound according to claim 1 wherein the compound is a compound of Formula (Ia) which can be represented by the following formula ##STR00082## a pharmaceutically acceptable acid or base addition salt thereof or a stereochemically isomeric form thereof. 9. A compound according to claim 8 wherein the compound is the diastereoisomer having a melting point of 210.degree. C., a pharmaceutically acceptable acid or base addition salt thereof or a stereochemically isomeric form thereof. 10. A compound according to claim 8 wherein the compound is the diastereoisomer, which exhibits the highest numerical pIC.sub.50 value in the M. smegmatis assay relative to the other diastereoisomer B of the same formula, or a pharmaceutically acceptable acid or base addition salt or a stereochemically isomeric form thereof. 11. A compound according to claim 8 wherein the compound is the enantiomeric form which exhibits the lowest numerical MIC value in the M. tuberculosis assay relative to the other enantiomeric forms of the same formula, or a pharmaceutically acceptable acid or base addition salt thereof. 12. A compound according to claim 8 wherein the compound is the enantiomeric form which exhibits the highest numerical pIC.sub.50 value in the M. smegmatis assay relative to the other enantiomeric forms of the same formula, or a pharmaceutically acceptable acid or base addition salt thereof. 13. A compound according to claim 8 wherein the compound is the enantiomeric form which exhibits a MIC value in the M. tuberculosis assay of less than or equal to 1 microgram/ml, or a pharmaceutically acceptable acid or base addition salt thereof. 14. A compound according to claim 8 wherein the compound is the enantiomeric form which exhibits a pIC.sub.50 value of greater than 7.5 in the M. smegmatis assay, or a pharmaceutically acceptable acid or base addition salt thereof. 15. A compound according to claim 1 wherein the compound is an enantiomeric form of Formula (Ia) which can be represented by the following formula ##STR00083## or a pharmaceutically acceptable acid addition salt thereof. 16. A compound according to claim 1 wherein the compound is an enantiomeric form of Formula (Ia) which can be represented by the following formula ##STR00084## and having the following optical rotation: [.alpha.].sub.D.sup.20=-166.98.degree. at a concentration of 0.505 g/100 ml in DMF, or a pharmaceutically acceptable acid or base addition salt thereof. 17. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in claim 1. 18. Method of treating a patient suffering from a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound according to claim 1. 19. A process for preparing a compound according to claim 1, characterized in that a compound of Formula (II) is reacted with a compound of Formula (III) according to the following reaction: ##STR00085## wherein R.sup.1, p, R.sup.2, R.sup.3, q, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are defined in claim 1. 20. A compound according to claim 1 wherein R.sup.3 is Ar-alkyl. 21. A compound according to claim 1 wherein q is an integer equal to 3. 22. A compound according to claim 1 wherein alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms. 23. A composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a therapeutically acceptable amount of a compound of claim 15. 24. The method according to claim 18 wherein the mycobacterial disease is tuberculosis.